Michael H. Davidson - 02 Mar 2026 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: NAMS
Reported as of: 02 Mar 2026
Net transaction value: -$14,753,258
SEC form: 4
Accepted by SEC: 02 Mar 2026, 18:08:05 UTC
Prior SEC filing: 26 Feb 2026
Next SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael H. Davidson

Key filing fact

Michael H. Davidson filed Form 4 for NewAmsterdam Pharma Co N.V. (NAMS) on 02 Mar 2026.

Key facts

This page summarizes Michael H. Davidson's Form 4 filing for NewAmsterdam Pharma Co N.V. (NAMS).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Mar 2026, 18:08.

Change

Previous filing in this sequence was filed on 26 Feb 2026.
Current net transaction value: -$14,753,258.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001573785 Primary reporting owner

Davidson Michael H.

Relationship: Chief Executive Officer, Director
Address: C/O NEWAMSTERDAM PHARMA COMPANY N.V., GOOIMEER 2-35, NAARDEN, NETHERLANDS
Signature: /s/ Michael H. Davidson
Signature date: 02 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NAMS transaction

Ordinary Shares

Options Exercise

Transaction value
Shares: +443,707
Change %: +255%
Price
Shares after: 617,851
Date: 02 Mar 2026
Ownership: Direct
Footnotes: F1

NAMS transaction

Ordinary Shares

Sale

Transaction value: $14,753,258
Shares: -443,707
Change %: -72%
Price: $33.25
Shares after: 174,144
Date: 02 Mar 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NAMS transaction Derivative

Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -443,707
Change %: -65%
Price: $0.000000
Shares after: 239,267
Date: 02 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 443,707
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The exercise price of the option is EUR 1.16392.

Footnote F2

The option was granted on November 22, 2022 to replace options originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the options vested on August 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.